Literature DB >> 33768319

TERT promoter mutation in sebaceous neoplasms.

María-Teresa Muñoz-Jiménez1, Leyla Blanco1, Yolanda Ruano1, Rosario Carrillo2, Ángel Santos-Briz3, Erika Riveiro-Falkenbach1, Luis Requena4, Heinz Kutzner5, María Concepción Garrido1, José-Luis Rodríguez-Peralto6.   

Abstract

TERT promoter (TERTp) mutations widely occur in multiple human neoplasms, and they have been related to different clinicopathological features. To date, this mutation has not been identified in sebaceous tumors. Here, we analyzed TERTp mutations in 91 sebaceous neoplasms (17 adenomas, 45 sebaceomas, and 29 carcinomas). We detected mutations in 26.7% (8 of 29) of sebaceous carcinomas by pyrosequencing and Sanger sequencing. No mutation was detected in adenomas or sebaceomas. The difference was significant between sebaceoma and carcinoma. The most frequent TERTp mutations were C228T and C250T in 37.5% (3 of 8) of mutated cases each one. The mutation was not associated with poor clinical evolution. Using NGS, 20 of 29 (68.5%) sebaceous carcinomas harbored mutations in 8 of the 30 genes analyzed (TP53, TERTp, EGFR, ATRX, PDGFRA, CDKN2A, PTEN, and ACVR1). With immunohistochemistry, only 1 of 8 (12.5%) TERTp-mutated carcinomas lacked mismatch repair (MMR) protein expression compared to 6 of 21 (31.6%) of non-mutated ones. Sebaceous carcinomas with MMR protein expression had significantly higher frequency of total mutations and TP53 and TERTp mutations than MMR protein-deficient carcinomas. In conclusion, TERTp mutation has been detected in sebaceous carcinomas, and its presence could be useful to differentiate sebaceous carcinoma from sebaceoma, a difficult histopathological challenge.

Entities:  

Keywords:  Mismatch repair proteins; Sebaceous neoplasms; Sequencing; TERT promoter mutation

Year:  2021        PMID: 33768319     DOI: 10.1007/s00428-021-03083-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  1 in total

1.  TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors.

Authors:  Diana Cantero; Manuela Mollejo; Juan M Sepúlveda; Nicky D'Haene; Myriam J Gutiérrez-Guamán; Ángel Rodríguez de Lope; Concepción Fiaño; Javier S Castresana; Laetitia Lebrun; Juan A Rey; Isabelle Salmon; Bárbara Meléndez; Aurelio Hernández-Laín
Journal:  Neurooncol Adv       Date:  2020-01-24
  1 in total
  2 in total

1.  The expression level of chicken telomerase reverse transcriptase in tumors induced by ALV-J is positively correlated with methylation and mutation of its promoter region.

Authors:  Yong Xiang; Qinxi Chen; Qingbo Li; Canxin Liang; Weisheng Cao
Journal:  Vet Res       Date:  2022-06-23       Impact factor: 3.829

2.  miR-196b-5p and miR-107 Expression Differentiates Ocular Sebaceous Carcinoma from Squamous Cell Carcinoma of the Conjunctiva.

Authors:  Ronald O B de Keizer; Anne L M Vriends; Gijsbert J Hötte; Dion A Paridaens; Erik A C Wiemer; Robert M Verdijk
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.